The clinical impact of ICOS signal in colorectal cancer patients
The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer...
Saved in:
| Published in | Oncoimmunology Vol. 5; no. 5; p. e1141857 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
03.05.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer (CRC) remains poorly understood. A tissue microarray (n = 310) was stained with the ICOS specific antibody and ICOS expression is decreased in patients with either lymphatic or distant metastasis and inversely associated with CEA level and TNM stage of CRC patients. Importantly, high ICOS expression is significantly correlated with overall survival (OS) of CRC patients (n = 230, p < 0.001), and ICOS expression is also proved to be an independent prognostic factor by multivariate analysis. Surgical excised CRC specimens (n = 26) were enzymatically digested to get the tumor-infiltrating leukocytes and ICOS is mainly expressed on CD4
+
T cells and its ligand ICOSL is detected on macrophages and tumor cells. ICOS expression level is associated with increased cytotoxic T lymphocyte antigen (CTLA)-4 (p < 0.001) and programmed death (PD-1) (p = 0.005) expression on T cells and more infiltrated CD8
+
T cells (p < 0.001). Interestingly, ICOS
+
CD4
+
cells isolated from tumor tissues have high T-bet and interferon (IFN)γ expression, the characteristics of Th1 cells, compared to ICOS
−
CD4
+
cells. In addition, the correlation between the percentage of ICOS
+
CD4
+
T cells in tumor tissue and peripheral blood was detected. Conclusively, expression of ICOS is associated with improved survival in CRC and percentage of ICOS
+
CD4
+
cells acting as Th1 cells in either primary tumor tissue or peripheral blood may be a clinical biomarker for good prognosis of CRC patients. |
|---|---|
| AbstractList | The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer (CRC) remains poorly understood. A tissue microarray (n = 310) was stained with the ICOS specific antibody and ICOS expression is decreased in patients with either lymphatic or distant metastasis and inversely associated with CEA level and TNM stage of CRC patients. Importantly, high ICOS expression is significantly correlated with overall survival (OS) of CRC patients (n = 230, p < 0.001), and ICOS expression is also proved to be an independent prognostic factor by multivariate analysis. Surgical excised CRC specimens (n = 26) were enzymatically digested to get the tumor-infiltrating leukocytes and ICOS is mainly expressed on CD4(+) T cells and its ligand ICOSL is detected on macrophages and tumor cells. ICOS expression level is associated with increased cytotoxic T lymphocyte antigen (CTLA)-4 (p < 0.001) and programmed death (PD-1) (p = 0.005) expression on T cells and more infiltrated CD8(+) T cells (p < 0.001). Interestingly, ICOS(+)CD4(+) cells isolated from tumor tissues have high T-bet and interferon (IFN)γ expression, the characteristics of Th1 cells, compared to ICOS(-)CD4(+) cells. In addition, the correlation between the percentage of ICOS(+)CD4(+) T cells in tumor tissue and peripheral blood was detected. Conclusively, expression of ICOS is associated with improved survival in CRC and percentage of ICOS(+)CD4(+) cells acting as Th1 cells in either primary tumor tissue or peripheral blood may be a clinical biomarker for good prognosis of CRC patients. The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer (CRC) remains poorly understood. A tissue microarray (n = 310) was stained with the ICOS specific antibody and ICOS expression is decreased in patients with either lymphatic or distant metastasis and inversely associated with CEA level and TNM stage of CRC patients. Importantly, high ICOS expression is significantly correlated with overall survival (OS) of CRC patients (n = 230, p < 0.001), and ICOS expression is also proved to be an independent prognostic factor by multivariate analysis. Surgical excised CRC specimens (n = 26) were enzymatically digested to get the tumor-infiltrating leukocytes and ICOS is mainly expressed on CD4 + T cells and its ligand ICOSL is detected on macrophages and tumor cells. ICOS expression level is associated with increased cytotoxic T lymphocyte antigen (CTLA)-4 (p < 0.001) and programmed death (PD-1) (p = 0.005) expression on T cells and more infiltrated CD8 + T cells (p < 0.001). Interestingly, ICOS + CD4 + cells isolated from tumor tissues have high T-bet and interferon (IFN)γ expression, the characteristics of Th1 cells, compared to ICOS − CD4 + cells. In addition, the correlation between the percentage of ICOS + CD4 + T cells in tumor tissue and peripheral blood was detected. Conclusively, expression of ICOS is associated with improved survival in CRC and percentage of ICOS + CD4 + cells acting as Th1 cells in either primary tumor tissue or peripheral blood may be a clinical biomarker for good prognosis of CRC patients. The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer (CRC) remains poorly understood. A tissue microarray (n = 310) was stained with the ICOS specific antibody and ICOS expression is decreased in patients with either lymphatic or distant metastasis and inversely associated with CEA level and TNM stage of CRC patients. Importantly, high ICOS expression is significantly correlated with overall survival (OS) of CRC patients (n = 230, p < 0.001), and ICOS expression is also proved to be an independent prognostic factor by multivariate analysis. Surgical excised CRC specimens (n = 26) were enzymatically digested to get the tumor-infiltrating leukocytes and ICOS is mainly expressed on CD4 + T cells and its ligand ICOSL is detected on macrophages and tumor cells. ICOS expression level is associated with increased cytotoxic T lymphocyte antigen (CTLA)-4 ( p < 0.001) and programmed death (PD-1) ( p = 0.005) expression on T cells and more infiltrated CD8 + T cells ( p < 0.001). Interestingly, ICOS + CD4 + cells isolated from tumor tissues have high T-bet and interferon (IFN)γ expression, the characteristics of Th1 cells, compared to ICOS − CD4 + cells. In addition, the correlation between the percentage of ICOS + CD4 + T cells in tumor tissue and peripheral blood was detected. Conclusively, expression of ICOS is associated with improved survival in CRC and percentage of ICOS + CD4 + cells acting as Th1 cells in either primary tumor tissue or peripheral blood may be a clinical biomarker for good prognosis of CRC patients. The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer (CRC) remains poorly understood. A tissue microarray (n = 310) was stained with the ICOS specific antibody and ICOS expression is decreased in patients with either lymphatic or distant metastasis and inversely associated with CEA level and TNM stage of CRC patients. Importantly, high ICOS expression is significantly correlated with overall survival (OS) of CRC patients (n = 230, p < 0.001), and ICOS expression is also proved to be an independent prognostic factor by multivariate analysis. Surgical excised CRC specimens (n = 26) were enzymatically digested to get the tumor-infiltrating leukocytes and ICOS is mainly expressed on CD4(+) T cells and its ligand ICOSL is detected on macrophages and tumor cells. ICOS expression level is associated with increased cytotoxic T lymphocyte antigen (CTLA)-4 (p < 0.001) and programmed death (PD-1) (p = 0.005) expression on T cells and more infiltrated CD8(+) T cells (p < 0.001). Interestingly, ICOS(+)CD4(+) cells isolated from tumor tissues have high T-bet and interferon (IFN)γ expression, the characteristics of Th1 cells, compared to ICOS(-)CD4(+) cells. In addition, the correlation between the percentage of ICOS(+)CD4(+) T cells in tumor tissue and peripheral blood was detected. Conclusively, expression of ICOS is associated with improved survival in CRC and percentage of ICOS(+)CD4(+) cells acting as Th1 cells in either primary tumor tissue or peripheral blood may be a clinical biomarker for good prognosis of CRC patients. |
| Author | Yu, Min-Hao Qi, Yang Zhang, Yan Luo, Yang Zhong, Ming Qin, Shao-Lan Mu, Yi-Fei |
| Author_xml | – sequence: 1 givenname: Yan surname: Zhang fullname: Zhang, Yan organization: School of Biomedical Engineering & Med-X Research Institute, Shanghai Jiao Tong University – sequence: 2 givenname: Yang surname: Luo fullname: Luo, Yang organization: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University – sequence: 3 givenname: Shao-Lan surname: Qin fullname: Qin, Shao-Lan organization: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University – sequence: 4 givenname: Yi-Fei surname: Mu fullname: Mu, Yi-Fei organization: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University – sequence: 5 givenname: Yang surname: Qi fullname: Qi, Yang organization: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University – sequence: 6 givenname: Min-Hao surname: Yu fullname: Yu, Min-Hao organization: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University – sequence: 7 givenname: Ming surname: Zhong fullname: Zhong, Ming email: drzhongming@hotmail.com organization: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27467961$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUU1PGzEUtKogElJ-Qqs99pJge732WkgVKCotElIOgMTN8r54wZXXDvYGxL-vV0kq4AC-2O9jZp7fHKGRD94g9I3gOcE1PqGEU4bp3ZxiwueEMFJX4guaDPnZUBi9eo_RcUp_cT4cV7yUh2hMBeNCcjJBZzcPpgBnvQXtCtutNfRFaIvLxfK6SPbeD1lfQHAhGuhzBNqDicVa99b4Pn1FB612yRzv7im6vfh1s_gzu1r-vlycX82A8bqfcUZbvSq1qamUTdnk6WRZs5wmgJluGGhBm5LVLQFJoeRA8k8bqCivJBdtOUU_t7zrTdOZFWTtqJ1aR9vp-KKCtuptxdsHdR-eFJMECyIywY8dQQyPG5N61dkExjntTdgkRWosaimGuabo-2ut_yL7teWG020DxJBSNK0C2-eFhEHaOkWwGnxSe5_U4JPa-ZTR1Tv0XuAz3NkWZ30bYqefQ3Qr1euX7E0bsy02qfJjin9Qyahc |
| CitedBy_id | crossref_primary_10_1016_j_genrep_2021_101388 crossref_primary_10_1016_j_semcancer_2022_06_009 crossref_primary_10_1080_14712598_2020_1693540 crossref_primary_10_1080_25785826_2021_1975228 crossref_primary_10_1080_2162402X_2017_1371896 crossref_primary_10_1158_2326_6066_CIR_20_0034 crossref_primary_10_1158_2326_6066_CIR_20_0274 crossref_primary_10_2139_ssrn_4061186 crossref_primary_10_3389_fimmu_2020_02104 crossref_primary_10_1016_j_intimp_2024_111949 crossref_primary_10_1016_j_imbio_2022_152181 crossref_primary_10_1016_j_ctrv_2023_102614 crossref_primary_10_3390_vaccines8010071 crossref_primary_10_3390_cancers13061297 crossref_primary_10_1002_cjp2_258 crossref_primary_10_1016_j_semcancer_2017_10_001 crossref_primary_10_18632_aging_102025 crossref_primary_10_1111_cas_15314 crossref_primary_10_3346_jkms_2023_38_e258 crossref_primary_10_3390_ijms25168775 crossref_primary_10_1186_s40425_019_0700_3 crossref_primary_10_1016_j_molimm_2018_02_017 crossref_primary_10_1016_j_isci_2022_104613 crossref_primary_10_3390_cancers14092241 crossref_primary_10_3389_fped_2019_00279 crossref_primary_10_3389_fonc_2022_946967 crossref_primary_10_3166_onco_2018_0011 crossref_primary_10_1016_j_intimp_2018_01_018 crossref_primary_10_1136_esmoopen_2019_000544 crossref_primary_10_3389_fimmu_2020_01052 crossref_primary_10_1007_s12253_018_0509_2 crossref_primary_10_3389_fimmu_2024_1391840 crossref_primary_10_1136_jitc_2024_010028 crossref_primary_10_1093_nargab_lqab016 crossref_primary_10_1111_jcmm_16547 crossref_primary_10_1016_j_cell_2020_02_015 crossref_primary_10_3390_cancers13123063 crossref_primary_10_4110_in_2020_20_e3 crossref_primary_10_3389_fmolb_2023_1277933 crossref_primary_10_3390_cancers15194793 crossref_primary_10_1007_s11684_018_0657_5 crossref_primary_10_1002_ame2_12355 crossref_primary_10_1080_14728222_2018_1444753 crossref_primary_10_1007_s10495_024_02022_8 crossref_primary_10_1186_s12885_020_06987_y crossref_primary_10_1002_cnr2_1160 crossref_primary_10_1136_jitc_2022_005980 crossref_primary_10_1172_JCI139905 crossref_primary_10_2147_PGPM_S301718 crossref_primary_10_2147_JIR_S401123 crossref_primary_10_3389_fphar_2021_681320 crossref_primary_10_1111_bjd_18040 crossref_primary_10_1080_15592294_2020_1754675 crossref_primary_10_1016_j_jconrel_2020_01_030 |
| Cites_doi | 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6 10.1016/j.ejca.2013.02.015 10.1038/cr.2012.178 10.1016/1074-7613(94)90071-X 10.1158/0008-5472.CAN-12-2409 10.1038/70932 10.1038/45582 10.1038/nrd1254 10.1038/nri727 10.1038/16717 10.1016/S1074-7613(00)00011-X 10.1084/jem.192.7.1027 10.1016/S1040-8428(02)00159-2 10.4049/jimmunol.165.9.5035 10.1016/S1074-7613(00)80480-X 10.1038/85330 10.1016/j.it.2013.07.003 10.1146/annurev.immunol.20.091101.091806 10.1084/jem.183.6.2541 10.4161/onci.23185 10.1084/jem.192.10.1501 10.1016/S1074-7613(00)80117-X 10.1016/j.immuni.2011.03.014 |
| ContentType | Journal Article |
| Copyright | 2016 The Author(s). Published with license by Taylor & Francis Group, LLC © Yan Zhang, Yang Luo, Shao-Lan Qin, Yi-Fei Mu, Yang Qi, Min-Hao Yu, and Ming Zhong. 2016 2016 The Author(s). Published with license by Taylor & Francis Group, LLC 2016 The Author(s) |
| Copyright_xml | – notice: 2016 The Author(s). Published with license by Taylor & Francis Group, LLC © Yan Zhang, Yang Luo, Shao-Lan Qin, Yi-Fei Mu, Yang Qi, Min-Hao Yu, and Ming Zhong. 2016 – notice: 2016 The Author(s). Published with license by Taylor & Francis Group, LLC 2016 The Author(s) |
| DBID | 0YH AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1080/2162402X.2016.1141857 |
| DatabaseName | Taylor & Francis Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Y. ZHANG ET AL |
| EISSN | 2162-402X |
| EndPage | e1141857 |
| ExternalDocumentID | PMC4910717 27467961 10_1080_2162402X_2016_1141857 1141857 |
| Genre | Original Article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | 00X 0YH 53G AAKDD ABUPF ACENM ACGFS ADBBV ADCVX AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS BABNJ BLEHA CCCUG DEAQA DGEBU DGFLZ EBS EJD EUPTU GROUPED_DOAJ H13 HYE KRBQP KSSTO KTTOD KWAYT KYCEM M4Z O9- OK1 RPM TDBHL TFL TFW TNTFI TTHFI AAYXX CITATION 4.4 ABDBF ACUHS EBD LJTGL NPM OVD TEORI 7X8 5PM EMOBN |
| ID | FETCH-LOGICAL-c468t-642fad3ae8299b3b21693846421c04ab4ca72b348f1c92c36c1108bc5265967f3 |
| IEDL.DBID | 0YH |
| ISSN | 2162-402X 2162-4011 |
| IngestDate | Thu Aug 21 13:41:26 EDT 2025 Fri Jul 11 08:51:26 EDT 2025 Thu Apr 03 06:57:53 EDT 2025 Thu Apr 24 23:01:58 EDT 2025 Tue Jul 01 02:07:43 EDT 2025 Wed Dec 25 09:01:33 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | colorectal cancer ICOS Th1 cell prognosis B7-CD28 family |
| Language | English |
| License | open-access: http://creativecommons.org/licenses/by-nc/3.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c468t-642fad3ae8299b3b21693846421c04ab4ca72b348f1c92c36c1108bc5265967f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Supplemental data for this article can be accessed on the publisher's website. These authors contributed equally to this work. |
| OpenAccessLink | https://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1141857 |
| PMID | 27467961 |
| PQID | 1807897169 |
| PQPubID | 23479 |
| ParticipantIDs | pubmed_primary_27467961 crossref_citationtrail_10_1080_2162402X_2016_1141857 informaworld_taylorfrancis_310_1080_2162402X_2016_1141857 crossref_primary_10_1080_2162402X_2016_1141857 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4910717 proquest_miscellaneous_1807897169 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05-03 |
| PublicationDateYYYYMMDD | 2016-05-03 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Oncoimmunology |
| PublicationTitleAlternate | Oncoimmunology |
| PublicationYear | 2016 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | cit0011 cit0022 cit0001 cit0012 cit0023 cit0020 cit0010 cit0021 cit0008 cit0019 cit0009 cit0006 cit0017 cit0007 cit0018 cit0004 cit0015 cit0005 cit0016 cit0002 cit0013 cit0003 cit0014 |
| References_xml | – ident: cit0017 doi: 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6 – ident: cit0009 doi: 10.1016/j.ejca.2013.02.015 – ident: cit0015 doi: 10.1038/cr.2012.178 – ident: cit0019 doi: 10.1016/1074-7613(94)90071-X – ident: cit0004 doi: 10.1158/0008-5472.CAN-12-2409 – ident: cit0013 doi: 10.1038/70932 – ident: cit0014 doi: 10.1038/45582 – ident: cit0023 doi: 10.1038/nrd1254 – ident: cit0001 doi: 10.1038/nri727 – ident: cit0006 doi: 10.1038/16717 – ident: cit0007 doi: 10.1016/S1074-7613(00)00011-X – ident: cit0021 doi: 10.1084/jem.192.7.1027 – ident: cit0010 doi: 10.1016/S1040-8428(02)00159-2 – ident: cit0011 doi: 10.4049/jimmunol.165.9.5035 – ident: cit0018 doi: 10.1016/S1074-7613(00)80480-X – ident: cit0022 doi: 10.1038/85330 – ident: cit0002 doi: 10.1016/j.it.2013.07.003 – ident: cit0016 doi: 10.1146/annurev.immunol.20.091101.091806 – ident: cit0020 doi: 10.1084/jem.183.6.2541 – ident: cit0005 doi: 10.4161/onci.23185 – ident: cit0012 doi: 10.1084/jem.192.10.1501 – ident: cit0003 doi: 10.1016/S1074-7613(00)80117-X – ident: cit0008 doi: 10.1016/j.immuni.2011.03.014 |
| SSID | ssj0000605639 |
| Score | 2.3591568 |
| Snippet | The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great... |
| SourceID | pubmedcentral proquest pubmed crossref informaworld |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e1141857 |
| SubjectTerms | B7-CD28 family colorectal cancer ICOS Original Research prognosis Th1 cell |
| Title | The clinical impact of ICOS signal in colorectal cancer patients |
| URI | https://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1141857 https://www.ncbi.nlm.nih.gov/pubmed/27467961 https://www.proquest.com/docview/1807897169 https://pubmed.ncbi.nlm.nih.gov/PMC4910717 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5aEbyIb9dHieB1dTdJs7s3pShVUA9aqKeQpAkKspV2e_Dfm8k-6IrSg8d9DISZSeZLMvMNQudaJYSNGQmljVTIEp6FEIZDpk2kFY1V6jvPPTzywZDdj3p1NuGsSquEPbQtiSL8Wg2TW6pZnRF3SWIOdwIjSMziQHYLfEaraI2AtzqXjl4HzTFL5OC6C8J17c5f0q2o1OIs_Q15_kygXIhIt1tos4KS-Lq0_TZaMfkOWi-bS37toivnAbgufMRlNSSeWHzXf3rGkLYBb3MMrNWw6rknDR4wxRXV6mwPDW9vXvqDsOqXEGrG0yJ0Wwkrx1Sa1MUYRRUBohWHLxiJdcSkYlomRFGW2lhnRFOuoQZAaWDIz3hi6T7q5JPcHCJs3DzVko8d-nOAiWjJkqRHlHUR3vQybQLEan0JXZGJQ0-LDxFXnKO1mgWoWVRqDtBFI_ZZsmksE8gWjSEKf4xhy54jgi6RPastJ9ycgYsQmZvJfCZiT7IPPEEBOigt2QyHQP-VjMcBSlo2bn4APu72l_z9zfNyMwe93O746B9jPkYb8OgzKukJ6hTTuTl1qKdQXe_XXX8c9Q1o1PcF |
| linkProvider | Taylor & Francis |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDLZgCMEF8aY8g8S10KZput5AE2iDbRzYpHGKmiwRSKhDW3fg3xP3MW0ItAPHNrEU2Un8JbE_A1wpGVE2ZNRNjCddFvHYRTfsMqU9JQNf1vPKc50ub_bZ4yAczOXCYFglnqFNQRSR79W4uPEyugqJu6E-x0eBAUZmcWS7RUKjVVgLrfPF8g3ea3N2z-JZvG69cJW885f0gltaIC39DXr-jKCcc0kP27BVYklyVxh_B1Z0ugvrRXXJrz24tVOAVJmPpEiHJCNDWo3nF4JxG_g3JUhbjdue_VI4Bcak5Fqd7EP_4b7XaLplwQRXMV7PXHuWMMkwSHTdOhkZSIpMKxZgMOorjyWSqSSiMmB146uYqoArTAKQCinyYx6Z4ABq6SjVR0C0Xagq4UML_yxioiphURRSaayL12GstAOs0pdQJZs4FrX4EH5JOlqpWaCaRalmB65nYp8FncYygXjeGCLL7zFMUXREBEtkLyvLCbto8CUkSfVoOhF-zrKPREEOHBaWnA2HYgGWmPsORAs2nnVAQu7FlvT9LSfmZhZ72ePx8T_GfAEbzV6nLdqt7tMJbGJTHl4ZnEItG0_1mYVAmTzP5_g3CzT5aQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB60ongR39ZnBK-ru9k0u3tTqqX1DVqop7BJExRkK7Y9-O-d2UexonjwuI-BMDPJfElmvgE4Mjrioi-4lzpfeyKSiUdh2BPG-kaHgY7zznM3t7LdFZe9RpVNOCzTKmkP7QqiiHytpsn91ndVRtwJDyTdCfQoMUsS2S3xGc3CXCPGWI8u7T-1J8csPsJ1DMJV7c5v0lNRaYqz9Cfk-T2B8ktEai3DUgkl2Vlh-xWYsdkqzBfNJT_W4BQ9gFWFj6yohmQDxzrNuwdGaRv0NmPEWk2rHj4Z8oB3VlKtDteh27p4bLa9sl-CZ4SMRx5uJVzaD1MbY4zRoeZEtIL4QvDA-CLVwqQR16GIXWASbkJpqAZAG2LIT2Tkwg2oZYPMbgGzOE9NKvuI_hAwcZOKKGpw7TDC20ZibB1EpS9lSjJx6mnxqoKSc7RSsyI1q1LNdTieiL0VbBp_CSRfjaFG-TGGK3qOqPAP2cPKcgrnDF2EpJkdjIcqyEn2iSeoDpuFJSfD4dR_JZFBHaIpG09-ID7u6S_Zy3POyy0QeuHuePsfYz6Ahfvzlrru3F7twCJ9yZMrw12ojd7Hdg8B0Ejv5y7-CZPl-Js |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+clinical+impact+of+ICOS+signal+in+colorectal+cancer+patients&rft.jtitle=Oncoimmunology&rft.au=Zhang%2C+Yan&rft.au=Luo%2C+Yang&rft.au=Qin%2C+Shao-Lan&rft.au=Mu%2C+Yi-Fei&rft.date=2016-05-03&rft.issn=2162-4011&rft.volume=5&rft.issue=5&rft.spage=e1141857&rft_id=info:doi/10.1080%2F2162402X.2016.1141857&rft_id=info%3Apmid%2F27467961&rft.externalDocID=27467961 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon |